Clinical trial NCT05476627: Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
Official title: Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chronic Kidney Diseases
Hypertension
Diabetes Mellitus
Hyperuricemia
Obesity
Keywords: chronic kidney disease
metabolic diseases
biomarker
functional imaging techniques
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2022-07-27
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population is consecutively enrolled from outpatient and inpatient department of our hospital.

Brief summary: With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.


Eligibility criteria: Inclusion Criteria:

* The diagnosis of metabolic diseases were confirmed;
* Be able to understand the process of the research;
* Volunteer for participation and be able to sign the informed consent.

Exclusion Criteria:

* Age \<18 yrs or \>80yrs;
* Patients with primary and secondary glomerular diseases
* Patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and/or renal tumors;
* Contraindications for MRI examination;
* Pregnant or lactation patients;
* Patients with unstable vital signs, failure of other organs or dysphoria.

Primary outcomes:
measure: Number of Participants with End Stage Renal Disease
timeFrame: 3 years
measure: Number of Participants with Adverse cardiovascular events
timeFrame: 3 years
measure: Number of Participants with all cause death
timeFrame: 3 years
Secondary outcomes:
measure: Number of Participants with eGFR decline
timeFrame: 3 years
measure: Number of Participants with Complications of CKD
timeFrame: 3 years
measure: Life quality assessment with short form-36 (SF-36)
timeFrame: 3 years
measure: Advanced Intelligence Assessment with Mini-Mental State Examination (MMSE)
timeFrame: 3 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital
name: Limeng Chen
role: PRINCIPAL_INVESTIGATOR
References: